FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Klepser

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Concepts & Ideas

Disorders

Physiology

Microbial Drug Resistance

Co-author Network

Publications

TOP 3
Donald G Klepser; Sara E Bisanz; Michael E Klepser
Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis.
Martha K Daddario; Jennifer K Hagerman; Michael E Klepser
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis.
Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Klepser (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Donald G Klepser; Sara E Bisanz; Michael E Klepser
Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis.
The American journal of managed care 2012;18(4):e145-54.
2010: Martha K Daddario; Jennifer K Hagerman; Michael E Klepser
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis.
Infection and drug resistance 2010;3():123-32.
2010: Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.
Drug design, development and therapy 2010;4():299-311.
2009: Erika J Ernst; Michael E Klepser; John A Bosso; Michael J Rybak; Elizabeth D Hermsen; Marisel Segarra-Newnham; Richard H Drew
Recommendations for training and certification for pharmacists practicing, mentoring, and educating in infectious diseases pharmacotherapy.
Pharmacotherapy 2009;29(4):482-8.
2008: Michael E Klepser
Seasonal and pandemic influenza: preparing pharmacists for the frontline.
Journal of the American Pharmacists Association : JAPhA 2008;48(2):312-4.
2007: Stephanie A Knechtel; Michael E Klepser
Safety of aerosolized amphotericin B.
Expert opinion on drug safety 2007;6(5):523-32.
2007: Jennifer K Hagerman; Stephanie A Knechtel; Michael E Klepser
Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature.
Expert opinion on pharmacotherapy 2007;8(4):467-75.
2007: Sarah E Raguckas; Heather L VandenBussche; Carrie Jacobs; Michael E Klepser
Pertussis resurgence: diagnosis, treatment, prevention, and beyond.
Pharmacotherapy 2007;27(1):41-52.
2006: Dana D Staat; Michael E Klepser
International adoption: issues in infectious diseases.
Pharmacotherapy 2006;26(9):1207-20.
2006: Michael E Klepser
Candida resistance and its clinical relevance.
Pharmacotherapy 2006;26(6 Pt 2):68S-75S.
2006: Jennifer K Hagerman; Kim E Hancock; Michael E Klepser
Aerosolised antibiotics: a critical appraisal of their use.
Expert opinion on drug delivery 2006;3(1):71-86.
2005: Russell Lewis; Nathan Wiederhold; Michael E Klepser
In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
Antimicrobial agents and chemotherapy 2005;49(3):945-51.
2005: Heather L Vandenbussche; Michael E Klepser
Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Lancet 2005;365(9459):547-8.
2004: Nisha P Shah; Prabashni Reddy; Joseph A Paladino; Peggy S McKinnon; Michael E Klepser; Chris L Pashos
Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model.
Current medical research and opinion 2004;20(6):779-90.
2004: Michael E Klepser
Role of nebulized antibiotics for the treatment of respiratory infections.
Current opinion in infectious diseases 2004;17(2):109-12.
2003: Michael E Klepser; Donald G Klepser; Erika J Ernst; John Brooks; Daniel J Diekema; Essy Mozaffari; Joseph Hendrickson; G V Doern
Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae.
Pharmacotherapy 2003;23(3):349-59.
2003: Holly L Hoffman; Michael E Klepser; Erika J Ernst; C Rosemarie Petzold; Loai Mohammed Sa'adah; G V Doern
Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.
Antimicrobial agents and chemotherapy 2003;47(2):739-46.
2002: Erika J Ernst; Ellen E Roling; C Rosemarie Petzold; Douglas J Keele; Michael E Klepser
In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.
Antimicrobial agents and chemotherapy 2002;46(12):3846-53.
2002: Ellen E Roling; Michael E Klepser; Ashley Wasson; Russell Lewis; Erika J Ernst; Michael A Pfaller
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
Diagnostic microbiology and infectious disease 2002;43(1):13-7.
2002: Erika J Ernst; Michael E Klepser; C Rosemarie Petzold; G V Doern
Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection.
Pharmacotherapy 2002;22(4):463-70.
2002: Patrick A Flume; Michael E Klepser
The rationale for aerosolized antibiotics.
Pharmacotherapy 2002;22(3 Pt 2):71S-79S.
2002: Michael E Klepser; Donald G Klepser
The dynamics of health care resource utilization.
Pharmacotherapy 2002;22(2 Pt 2):39S-44S.
2002: Russell Lewis; D J Diekema; S A Messer; Michael A Pfaller; Michael E Klepser
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species.
The Journal of antimicrobial chemotherapy 2002;49(2):345-51.
2002: Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.
Antimicrobial agents and chemotherapy 2002;46(2):578-81.
2002: Michael E Klepser
Amphotericin B in lung transplant recipients.
The Annals of pharmacotherapy 2002;36(1):167-9.
2001: D J Keele; V C DeLallo; Russell Lewis; Erika J Ernst; Michael E Klepser
Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.
Diagnostic microbiology and infectious disease 2001;41(3):121-6.
2001: Michael E Klepser
Antifungal resistance among Candida species.
Pharmacotherapy 2001;21(8 Pt 2):124S-132S.
2001: Michael E Klepser
New insights in medical mycology: focus on fungal infections. Introduction.
Pharmacotherapy 2001;21(8 Pt 2):109S-110S.
2001: Michael E Klepser; Erika J Ernst; C Rosemarie Petzold; Paul R Rhomberg; G V Doern
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Antimicrobial agents and chemotherapy 2001;45(3):673-8.
2000: S M Gunderson; Henry Hoffman; Erika J Ernst; Michael A Pfaller; Michael E Klepser
In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect.
Antimicrobial agents and chemotherapy 2000;44(10):2887-90.
2000: Michael E Klepser; D Malone; Russell Lewis; Erika J Ernst; Michael A Pfaller
Evaluation of voriconazole pharmacodynamics using time-kill methodology.
Antimicrobial agents and chemotherapy 2000;44(7):1917-20.
2000: Erika J Ernst; Michael E Klepser; Teresa B Klepser; C H Nightingale; Lawrence G Hunsicker
Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers.
Pharmacotherapy 2000;20(6):657-61.
2000: Russell Lewis; Michael E Klepser; Erika J Ernst; MIchael Snabes; Ronald Jones
Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection.
Diagnostic microbiology and infectious disease 2000;37(1):51-5.
2000: Erika J Ernst; Michael E Klepser; Michael A Pfaller
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
Antimicrobial agents and chemotherapy 2000;44(4):1108-11.
2000: Holly L Hoffman; Erika J Ernst; Michael E Klepser
Novel triazole antifungal agents.
Expert opinion on investigational drugs 2000;9(3):593-605.
2000: Russell Lewis; Michael E Klepser; Michael A Pfaller
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods.
Diagnostic microbiology and infectious disease 2000;36(2):101-5.
2000: Teresa B Klepser; William R Doucette; M R Horton; L M Buys; Michael E Ernst; J K Ford; James D Hoehns; HA Kautzman; Craig Logemann; John M Swegle; M Ritho; Michael E Klepser
Assessment of patients' perceptions and beliefs regarding herbal therapies.
Pharmacotherapy 2000;20(1):83-7.
1999: Russell Lewis; Michael E Klepser; Erika J Ernst; Brian C Lund; Douglas J Biedenbach; Ronald Jones
Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.
Antimicrobial agents and chemotherapy 1999;43(8):2005-9.
1999: Russell Lewis; Michael E Klepser
The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1999;56(6):525-33; quiz 534-5.
1999: Erika J Ernst; Michael E Klepser; Michael E Ernst; Shawn A Messer; Michael A Pfaller
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.
Diagnostic microbiology and infectious disease 1999;33(2):75-80.
1999: Teresa B Klepser; Michael E Klepser
Unsafe and potentially safe herbal therapies.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1999;56(2):125-38; quiz 139-41.
1998: Michael E Klepser; Russell Lewis; Michael A Pfaller
Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options.
The Annals of pharmacotherapy 1998;32(12):1353-61.
1998: Michael E Klepser; Michael A Pfaller
Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994.
Journal of clinical microbiology 1998;36(12):3653-6.
1998: Erika J Ernst; Michael E Klepser; Michael A Pfaller
In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time.
Diagnostic microbiology and infectious disease 1998;32(3):205-10.
1998: Brian C Lund; Erika J Ernst; Michael E Klepser
Strategies in the treatment of penicillin-resistant Streptococcus pneumoniae.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1998;55(19):1987-94.
1998: Michael E Klepser; K B Patel; D P Nicolau; Richard Quintiliani; C H Nightingale
Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Pharmacotherapy 1998;18(5):1069-74.
1998: Michael E Klepser; Erika J Ernst; Michael E Ernst; Shawn A Messer; Michael A Pfaller
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
Antimicrobial agents and chemotherapy 1998;42(6):1387-91.
1998: Russell Lewis; Brian C Lund; Michael E Klepser; Erika J Ernst; Michael A Pfaller
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.
Antimicrobial agents and chemotherapy 1998;42(6):1382-6.
1998: Russell Lewis; Michael E Klepser; Michael A Pfaller
Update on clinical antifungal susceptibility testing for Candida species.
Pharmacotherapy 1998;18(3):509-15.
1998: Michael E Klepser; Erika J Ernst; Russell Lewis; Michael E Ernst; Michael A Pfaller
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.
Antimicrobial agents and chemotherapy 1998;42(5):1207-12.
1998: Michael E Klepser; EJ Wolfe; Michael A Pfaller
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
The Journal of antimicrobial chemotherapy 1998;41(3):397-401.
1997: Michael E Klepser; Erika J Ernst; Michael E Ernst; Michael A Pfaller
Growth medium effect on the antifungal activity of LY 303366.
Diagnostic microbiology and infectious disease 1997;29(4):227-31.
1997: Michael E Ernst; Michael E Klepser; M Fouts; MN Marangos
Tetanus: pathophysiology and management.
The Annals of pharmacotherapy 1997;31(12):1507-13.
1997: Michael E Ernst; Erika J Ernst; Michael E Klepser
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1997;54(22):2569-84.
1997: Michael E Klepser; E J Ernst; Michael A Pfaller
Update on antifungal resistance.
Trends in microbiology 1997;5(9):372-5.
1997: Michael E Klepser; EJ Wolfe; Ronald Jones; C H Nightingale; Michael A Pfaller
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.
Antimicrobial agents and chemotherapy 1997;41(6):1392-5.
1997: Michael E Klepser; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis.
Antimicrobial agents and chemotherapy 1997;41(3):630-5.
1997: MN Marangos; Z Zhu; David P Nicolau; Michael E Klepser; Charles H Nightingale
Disposition of ofloxacin in female New Zealand white rabbits.
Journal of veterinary pharmacology and therapeutics 1997;20(1):17-20.
1997: Michael E Klepser; MN Marangos; Z Zhu; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1997;41(2):435-9.
1997: Michael E Klepser; Teresa B Klepser
Drug treatment of HIV-related opportunistic infections.
Drugs 1997;53(1):40-73.
1996: Michael E Ernst; Michael E Klepser; E J Wolfe; Michael A Pfaller
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.
Diagnostic microbiology and infectious disease 1996;26(3-4):125-31.
1996: Michael E Klepser; Mary Anne Banevicius; Richard Quintiliani; Charles H Nightingale
Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods.
Antimicrobial agents and chemotherapy 1996;40(8):1941-4.
1996: Michael E Klepser; Z Zhu; David P Nicolau; Mary Anne Banevicius; P P Belliveau; J W Ross; L Broisman; Richard Quintiliani; Charles H Nightingale
Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS.
Pharmacotherapy 1996;16(4):656-62.
1995: Michael E Klepser; K B Patel; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1995;39(11):2503-10.
1995: Michael E Klepser; MN Marangos; K B Patel; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Clinical pharmacokinetics of newer cephalosporins.
Clinical pharmacokinetics 1995;28(5):361-84.